Dysregulation of striato-nigral GABAergic pathway by chronic haloperidol treatment: the role of dopamine D1 receptor in the substantia nigra pars reticulata on the development of tardive dyskinesia.
Shirakawa
O
O
Department of Psychiatry and Neurology, Kobe University School of Medicine.
Maeda
K
K
Sakai
K
K
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000503:physiopathology; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology*; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D008409:Mastication / Q000187:drug effects / Q000502:physiology; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000187:drug effects* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D013239:Stereotyped Behavior / Q000187:drug effects / Q000502:physiology; D013378:Substantia Nigra / Q000187:drug effects* / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D006220:Haloperidol